Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.60
Percentage change 2.93	%

Peers: BMRN RARE SRPT VYGR FOLD QURE CRSP AGIO CLLS PFE

| Held by: VTI IWM XBI VXF IWN IBB PJP SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-4.56	Insider Own	1.31%	Shs Outstand	87.03M	Perf Week	1.15%
Market Cap	1.83B	Forward P/E	-	EPS next Y	-1.12	Insider Trans	-13.80%	Shs Float	85.89M	Perf Month	21.82%
Income	-351.52M	PEG	-	EPS next Q	-0.57	Inst Own	97.72%	Short Float	11.15%	Perf Quarter	17.73%
Sales	203.45M	P/S	9.01	EPS this Y	-143.28%	Inst Trans	-6.84%	Short Ratio	7.19	Perf Half Y	121.58%
Book/sh	-0.39	P/B	-	EPS next Y	69.22%	ROA	-52.19%	Short Interest	9.58M	Perf Year	125.86%
Cash/sh	3.19	P/C	6.60	EPS next 5Y	-	ROE	-279.94%	52W Range	5.12 - 21.56	Perf YTD	20.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.34%	ROI	-117.93%	52W High	-2.37%	Beta	0.73
Dividend TTM	-	Quick Ratio	1.68	Sales past 5Y	2.15%	Gross Margin	73.91%	52W Low	311.13%	ATR (14)	1.08
Dividend Ex-Date	-	Current Ratio	1.71	EPS Y/Y TTM	-3.48%	Oper. Margin	-137.48%	RSI (14)	63.17	Volatility	6.03% 5.79%
Employees	380	Debt/Eq	-	Sales Y/Y TTM	-2.96%	Profit Margin	-172.78%	Recom	1.25	Target Price	28.47
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	28.50%	Payout	-	Rel Volume	0.78	Prev Close	20.45
Sales Surprise	3.33%	EPS Surprise	-4.62%	Sales Q/Q	69.56%	Earnings	Oct 31 BMO	Avg Volume	1.33M	Price	21.05
SMA20	9.79%	SMA50	13.64%	SMA200	67.05%	Trades		Volume	1,044,523	Change	2.93%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22
Dec-05-22	Initiated	Wells Fargo	Overweight	$28
Sep-21-22	Initiated	Bryan Garnier	Sell	$17
Jul-14-22	Resumed	Canaccord Genuity	Buy	$49 → $42

Show Previous Ratings

Jan-13-25 07:00AM	Travere Therapeutics Provides Corporate Update and 2025 Outlook (GlobeNewswire)
Jan-06-25 04:30PM	Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-03-24 05:51AM	Japan MHLW grants orphan drug status to Renalys' sparsentan for IgAN treatment (Pharmaceutical Business Review)
Nov-25-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-13-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Loading…
Nov-12-24 04:05PM	Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Nov-07-24 09:05PM	Travere Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +12.40%
04:01PM	Travere Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-04-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-01-24 03:05AM	Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ... (GuruFocus.com)
Oct-31-24 07:00AM	Travere Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:13AM	Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-28-24 08:35AM	Travere presents data reinforcing clinical benefit of FILSPARI in IgAN (TipRanks)
Oct-26-24 07:01AM	Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 (GlobeNewswire)
04:30PM	Loading…
Oct-21-24 04:30PM	Travere Therapeutics to Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-17-24 07:01AM	Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (GlobeNewswire)
02:30AM	CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI (sparsentan) for the treatment of IgA Nephropathy (PR Newswire)
Oct-14-24 04:30PM	Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire) +6.28%
Oct-09-24 03:50PM	Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com) +15.65%
08:02AM	Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales (Insider Monkey)
Sep-26-24 04:01PM	Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up (GlobeNewswire) -6.85%
Sep-12-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.98%
Sep-10-24 04:01PM	Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire) +10.57%
Sep-05-24 05:34PM	Travere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (GlobeNewswire)
Aug-22-24 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 (GlobeNewswire)
Aug-06-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.39%
Aug-01-24 04:01PM	Travere Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 04:30PM	Travere Therapeutics to Report Second Quarter 2024 Financial Results (GlobeNewswire)
08:43AM	Loading…
Jul-10-24 08:43AM	Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength? (Zacks)
Jul-08-24 04:30PM	Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference (GlobeNewswire) +10.52% +8.83%
Jun-24-24 07:32AM	Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar? (Zacks) +6.57%
Jun-11-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-09-24 04:30PM	Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress (GlobeNewswire)
May-08-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:07AM	Travere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ... (GuruFocus.com)
May-06-24 08:59PM	TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:30PM	Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings (Zacks)
05:10PM	Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Travere Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 04:30PM	Travere Therapeutics to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 07:05AM	Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy (GlobeNewswire) -5.05%
03:00AM	CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy (PR Newswire)
Apr-04-24 04:30PM	Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International (GlobeNewswire)
Apr-03-24 04:30PM	Travere Therapeutics to Present Abstracts on FILSPARI (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association (GlobeNewswire)
Mar-13-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.16% -7.61%
Mar-11-24 07:05AM	Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN) (GlobeNewswire) -7.74%
Feb-26-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-23-24 07:05AM	Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy (GlobeNewswire)
02:00AM	CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy (PR Newswire)
Feb-16-24 09:52AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript (Insider Monkey) -6.18%
Feb-15-24 04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +5.94%
Feb-08-24 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-01-24 04:30PM	Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-25-24 04:05PM	Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations (GlobeNewswire) -6.01%
Jan-08-24 07:00AM	Travere Therapeutics Provides Corporate Update and 2024 Outlook (GlobeNewswire) +13.66%
Jan-02-24 04:30PM	Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.34%
Dec-14-23 07:30AM	Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU) (GlobeNewswire)
Dec-04-23 04:05PM	Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS (GlobeNewswire) +17.65%
Nov-21-23 04:30PM	Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-09-23 06:26PM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Earnings Call Transcript (Insider Monkey) -14.06%
Nov-07-23 04:01PM	Travere Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire) +8.13% -11.84%
Nov-03-23 10:46AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire) +5.93%
Oct-24-23 04:30PM	Travere Therapeutics to Report Third Quarter 2023 Financial Results (GlobeNewswire) -5.43%
Oct-13-23 04:30PM	Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire)
Oct-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.31%
Sep-26-23 04:30PM	Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023) (GlobeNewswire) +5.96%
Sep-22-23 09:38AM	Wayfair upgraded, Deere downgraded: Wall Street's top analyst calls (The Fly)
Sep-21-23 07:30AM	Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan (GlobeNewswire) -40.68%
Sep-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-23 08:30AM	Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals (GlobeNewswire)
08:30AM	Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Aug-31-23 04:30PM	Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference (GlobeNewswire) +8.26%
Aug-24-23 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 (GlobeNewswire)
Aug-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-23 06:03AM	News Flash: Analysts Just Made A Notable Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasts (Simply Wall St.)
Aug-03-23 04:01PM	Travere Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 12:28PM	J.P. Morgan Recommends These 2 Strong Buy Stocks Including One With 90% Upside Potential (TipRanks)
Jul-20-23 04:30PM	Travere Therapeutics to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-17-23 08:00AM	Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals (GlobeNewswire)
08:00AM	Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Jul-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-08-23 04:30PM	Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023 (GlobeNewswire) -7.39%
Jun-01-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-31-23 07:00AM	Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria (GlobeNewswire) +9.02%
May-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-04-23 04:01PM	Travere Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire) +5.20%
May-01-23 04:05PM	Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis (GlobeNewswire) -30.78%
Apr-26-23 04:30PM	Travere Therapeutics to Report First Quarter 2023 Financial Results (GlobeNewswire)
Apr-13-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-23 04:30AM	Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 (GlobeNewswire)
Mar-28-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.68%
Mar-23-23 04:30PM	Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023 (GlobeNewswire)
Mar-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:30PM	Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023 (GlobeNewswire)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Jan 22 '25	Sale	19.46	2,437	47,424	83,170	Jan 23 08:40 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 22 '25	Sale	19.46	10,736	208,923	351,239	Jan 23 08:39 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Jan 22 '25	Sale	19.46	2,437	47,424	76,933	Jan 23 08:37 PM
Baynes Roy D.	Director	Jan 23 '25	Option Exercise	17.50	16,000	280,000	47,000	Jan 23 08:36 PM
Baynes Roy D.	Director	Jan 23 '25	Sale	20.00	16,000	320,000	31,000	Jan 23 08:36 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Jan 22 '25	Sale	18.94	1,584	30,002	106,374	Jan 23 08:35 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Jan 22 '25	Sale	18.94	865	16,384	73,730	Jan 23 08:33 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Jan 22 '25	Sale	18.94	925	17,520	54,002	Jan 23 08:31 PM
ROY D BAYNES	Director	Jan 23 '25	Proposed Sale	20.00	16,000	320,000		Jan 23 04:14 PM
Dube Eric M	Officer	Jan 22 '25	Proposed Sale	19.46	10,736	208,923		Jan 22 10:34 AM
REED ELIZABETH E	Officer	Jan 22 '25	Proposed Sale	19.46	2,437	47,424		Jan 22 10:18 AM
ROTE WILLIAM E.	Officer	Jan 22 '25	Proposed Sale	19.46	2,437	47,424		Jan 22 09:36 AM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 03 '25	Sale	19.10	2,066	39,461	59,883	Jan 06 07:21 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 06 '25	Sale	18.76	440	8,254	59,443	Jan 06 07:21 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 26 '24	Option Exercise	12.67	15,000	190,050	69,927	Dec 27 07:47 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 26 '24	Sale	17.22	15,000	258,277	54,927	Dec 27 07:47 PM
SANDRA CALVIN	Officer	Dec 26 '24	Proposed Sale	17.22	15,000	258,278		Dec 26 04:13 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 25 '24	Option Exercise	12.67	15,000	190,050	67,017	Nov 25 09:00 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 25 '24	Sale	18.30	12,090	221,258	54,927	Nov 25 09:00 PM
Calvin Sandra	Officer	Nov 25 '24	Proposed Sale	18.30	12,090	221,258		Nov 25 05:59 PM
LYONS GARY A	Director	Oct 04 '24	Option Exercise	10.48	40,000	419,200	91,000	Oct 04 07:15 PM
LYONS GARY A	Director	Oct 04 '24	Sale	14.73	40,000	589,101	51,000	Oct 04 07:15 PM
GARY A LYONS	Officer	Oct 04 '24	Proposed Sale	13.65	40,000	546,000		Oct 04 04:21 PM
Meckler Jeffrey A	Director	Sep 30 '24	Option Exercise	10.48	40,000	419,200	121,000	Sep 30 08:38 PM
Meckler Jeffrey A	Director	Sep 30 '24	Sale	14.06	40,000	562,324	81,000	Sep 30 08:38 PM
JEFFREY MECKLER	Director	Sep 30 '24	Proposed Sale	14.06	40,000	562,324		Sep 30 04:22 PM
Calvin Sandra	Officer	Sep 11 '24	Proposed Sale	14.80	15,000	222,000		Sep 11 06:29 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Sep 10 '24	Sale	12.98	684	8,878	61,949	Sep 10 04:05 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Sep 09 '24	Sale	11.52	4,387	50,538	84,455	Sep 09 09:20 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Sep 09 '24	Sale	11.52	4,387	50,538	78,633	Sep 09 09:20 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Sep 09 '24	Sale	11.52	21,125	243,360	361,975	Sep 09 09:20 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Sep 09 '24	Sale	11.52	2,191	25,240	62,633	Sep 09 09:20 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Sep 09 '24	Sale	11.52	2,191	25,240	107,958	Sep 09 09:20 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 09 '24	Sale	11.52	2,490	28,685	74,595	Sep 09 09:20 PM
REED ELIZABETH E	Officer	Sep 09 '24	Proposed Sale	11.52	4,387	50,538		Sep 09 10:54 AM
ROTE WILLIAM E.	Officer	Sep 09 '24	Proposed Sale	11.52	4,387	50,538		Sep 09 10:35 AM
Dube Eric M	Officer	Sep 09 '24	Proposed Sale	11.52	21,125	243,360		Sep 09 10:34 AM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 04 '24	Sale	9.51	514	4,888	70,335	Sep 05 09:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 11 '24	Sale	6.74	54	364	70,849	Apr 12 04:05 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 01 '24	Sale	8.70	19,122	166,435	350,600	Feb 02 04:06 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Feb 01 '24	Sale	8.71	4,764	41,495	80,720	Feb 02 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 01 '24	Sale	8.53	2,820	24,058	52,017	Feb 02 04:05 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Feb 01 '24	Sale	8.71	4,764	41,495	76,270	Feb 02 04:05 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 01 '24	Sale	8.53	4,195	35,789	99,503	Feb 02 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 01 '24	Sale	8.53	2,174	18,547	58,074	Feb 02 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 01 '24	Sale	8.53	3,818	32,573	70,903	Feb 02 04:05 PM

Open in Screener

NTRA

Natera Inc

Jan 30 • 04:00PM ET

176.27

Dollar change +8.05
Percentage change 4.79	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH TXG EXAS QGEN FLGT TWST MYGN CDNA BNGO

| Held by: VTI VB VXF VBK XBI IBB IWP ARKK IWF IWR

Index	-	P/E	-	EPS (ttm)	-1.77	Insider Own	5.70%	Shs Outstand	132.02M	Perf Week	2.59%
Market Cap	23.27B	Forward P/E	-	EPS next Y	-1.20	Insider Trans	-7.89%	Shs Float	124.49M	Perf Month	9.99%
Income	-214.69M	PEG	-	EPS next Q	-0.38	Inst Own	90.79%	Short Float	3.40%	Perf Quarter	46.03%
Sales	1.53B	P/S	15.19	EPS this Y	60.38%	Inst Trans	1.61%	Short Ratio	3.12	Perf Half Y	80.33%
Book/sh	7.08	P/B	24.91	EPS next Y	19.73%	ROA	-14.14%	Short Interest	4.24M	Perf Year	165.43%
Cash/sh	6.99	P/C	25.23	EPS next 5Y	-	ROE	-25.82%	52W Range	64.74 - 183.00	Perf YTD	11.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.28%	ROI	-16.98%	52W High	-3.68%	Beta	1.65
Dividend TTM	-	Quick Ratio	4.23	Sales past 5Y	38.10%	Gross Margin	57.66%	52W Low	172.27%	ATR (14)	7.74
Dividend Ex-Date	-	Current Ratio	4.39	EPS Y/Y TTM	60.70%	Oper. Margin	-15.80%	RSI (14)	59.47	Volatility	4.88% 4.80%
Employees	3293	Debt/Eq	0.54	Sales Y/Y TTM	54.94%	Profit Margin	-14.01%	Recom	1.52	Target Price	192.60
Option/Short	Yes / Yes	LT Debt/Eq	0.44	EPS Q/Q	73.04%	Payout	-	Rel Volume	1.18	Prev Close	168.22
Sales Surprise	21.67%	EPS Surprise	54.75%	Sales Q/Q	63.90%	Earnings	Nov 12 AMC	Avg Volume	1.36M	Price	176.27
SMA20	4.62%	SMA50	6.06%	SMA200	39.16%	Trades		Volume	1,598,615	Change	4.79%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90
Jan-06-22	Resumed	Piper Sandler	Overweight	$110
Oct-15-21	Resumed	Cowen	Outperform	$150
Jun-15-21	Initiated	Raymond James	Mkt Perform
May-25-21	Initiated	Wells Fargo	Overweight	$110
Jan-28-21	Initiated	Truist	Buy	$143

Show Previous Ratings

Jan-28-25 08:02AM	Heres Why Natera (NTRA) Surged in Q4 (Insider Monkey)
Jan-27-25 09:42AM	Natera reports new data from Phase III study of colorectal cancer detection test (Medical Device Network)
Jan-25-25 10:05AM	Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer (Business Wire)
Jan-21-25 06:05PM	Natera to Present New Data at the 2025 ASCO GI Symposium (Business Wire) +5.75%
04:03PM	Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone (Investor's Business Daily)
09:00AM	Loading…
Jan-17-25 09:00AM	Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year (Business Wire) -6.02%
Jan-16-25 04:05PM	Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?' (Investor's Business Daily)
Jan-15-25 07:00AM	Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection (Business Wire)
Jan-12-25 07:20PM	Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024 (Business Wire)
Jan-09-25 08:15AM	Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings (Motley Fool)
Jan-07-25 09:00AM	Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-03-25 02:03PM	Six IBD 50 Stocks Bear Gifts Even As Santa Claus Rally Fizzles (Investor's Business Daily)
Dec-17-24 09:35AM	Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
08:00AM	Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics (Business Wire)
06:53AM	What Makes Natera (NTRA) a Top Stock Pick for Billionaire Stanley Druckenmiller? (Insider Monkey)
08:21AM	Loading…
Dec-13-24 08:21AM	Natera enrolls 1st patients in SAGITTARIUS clinical trial in colon cancer (TipRanks)
Dec-12-24 08:00AM	Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer (Business Wire)
Dec-09-24 08:00AM	Natera and MyOme Announce Launch of iPRS for Breast Cancer Risk Assessment (Business Wire)
Dec-03-24 08:06AM	Strong Volume Growth Lifted Natera (NTRA) in Q3 (Insider Monkey)
Dec-02-24 02:40PM	Why Is Natera, Inc. (NTRA) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
08:00AM	Clinical Validation Study on Nateras Fetal RhD NIPT Published in Obstetrics and Gynecology (Business Wire)
08:00AM	Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology (Business Wire)
05:00AM	Guardant awarded nearly $293M in false ad trial against Natera (MedTech Dive)
Nov-27-24 09:00AM	Natera Announces Medicare Coverage for Prospera in Single Lung Transplant Recipients (Business Wire)
Nov-25-24 07:57PM	Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium (Business Wire)
05:09PM	Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal (PR Newswire)
03:51PM	Natera Issues Statement on Guardant Health Litigation (Business Wire)
09:00AM	Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 RandD Leader of the Year (Business Wire)
09:00AM	Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year (Business Wire)
Nov-21-24 05:31PM	Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM (Business Wire)
09:09PM	Loading…
Nov-14-24 09:09PM	Stanley Druckenmiller's Strategic Emphasis on Natera Inc in Q3 2024 (GuruFocus.com) -6.13%
Nov-13-24 10:25AM	Natera Stock Explodes 20% After Record-Breaking Q3--Is This Biotech Giant Just Getting Started? (GuruFocus.com) +19.13%
02:17AM	Natera Inc (NTRA) Q3 2024 Earnings Call Highlights: Record Revenue and Raised Guidance Amid ... (GuruFocus.com)
12:04AM	Decoding Natera Inc (NTRA): A Strategic SWOT Insight (GuruFocus.com)
Nov-12-24 06:30PM	Natera (NTRA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:55PM	Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:48PM	Natera: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Third Quarter 2024 Financial Results (Business Wire)
07:00AM	Natera Announces Completion of Signatera Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer (Business Wire)
Nov-11-24 07:03AM	Natera Inc (NTRA) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-08-24 09:00AM	Natera to Participate in Upcoming Investor Conferences (Business Wire)
Nov-01-24 09:00AM	Natera to Report its Third Quarter 2024 Results on November 12, 2024 (Business Wire)
Oct-23-24 12:00PM	All You Need to Know About Natera (NTRA) Rating Upgrade to Strong Buy (Zacks)
Oct-22-24 09:00AM	Natera to Present New Renasight Data at ASN Kidney Week 2024 (Business Wire)
Oct-06-24 09:12AM	Natera Inc. (NTRA): Hedge Funds Are Bullish On This NASDAQ Stock Right Now (Insider Monkey)
Sep-23-24 04:06PM	Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase (Business Wire)
10:07AM	Should You Be Confident in the Growth Potential of Natera (NTRA)? (Insider Monkey)
Sep-16-24 07:13AM	ESMO 2024: Natera showcases chemotherapy prediction benefit of cDNA test (Medical Device Network)
05:17AM	Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO (Business Wire)
Sep-14-24 02:16PM	First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival (Business Wire)
Sep-11-24 05:59AM	Natera (NTRA) Continued its Incremental Strong Results (Insider Monkey)
Sep-09-24 11:42AM	DNA Testing Stock Taps AI Amid 85% Surge (Investor's Business Daily)
Sep-08-24 08:22PM	Natera to Present New Signatera Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival (Business Wire)
Sep-06-24 10:24AM	What Makes Natera (NTRA) an Investment Bet? (Insider Monkey)
Sep-03-24 02:37AM	Natera (NTRA) Rose After Revenues And Profit Margins Beat Estimates (Insider Monkey)
Aug-31-24 11:48AM	Billionaire Stan Druckenmiller Is Betting On Natera, Inc. (NTRA) (Insider Monkey)
Aug-29-24 02:07PM	The Committee's Comeback Kids: Trade Desk, Sweetgreen, Natera, Samsara, PayPal and Leidos (CNBC TV)
Aug-28-24 09:00AM	Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-27-24 03:19PM	PepsiCo, Inc. (PEP): Among Morgan Stanleys Highest Conviction Stocks (Insider Monkey)
03:16PM	Natera, Inc. (NTRA): Among Morgan Stanley's Highest Conviction Stocks (Insider Monkey)
Aug-17-24 01:01AM	Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Aug-10-24 01:01AM	Decoding Natera Inc (NTRA): A Strategic SWOT Insight (GuruFocus.com)
Aug-09-24 09:46AM	Q2 2024 Natera Inc Earnings Call (Thomson Reuters StreetEvents) +6.38%
Aug-08-24 07:00PM	Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics (Zacks) +7.31%
05:19PM	Natera: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-06-24 09:00AM	Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-30-24 04:05PM	Natera to Report its Second Quarter 2024 Results on August 8, 2024 (Business Wire) -5.80%
Jul-29-24 10:53AM	Natera touts positive results for Merkel cell carcinoma surveillance test (Medical Device Network)
Jul-27-24 01:00AM	Insider Sale: CFO Michael Brophy Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Jul-26-24 08:00AM	New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma (Business Wire)
Jul-25-24 10:02AM	Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-18-24 01:00AM	Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com) -8.35%
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
Jul-03-24 08:53AM	Natera (NTRA) Soared After a 43% Increase In Revenue (Insider Monkey)
07:00AM	Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy (Business Wire)
05:30AM	Insider Sale: CEO and President Steven Chapman Sells 37,500 Shares of Natera Inc (NTRA) (GuruFocus.com)
Jun-27-24 07:00AM	Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer (Business Wire)
Jun-19-24 03:10AM	Insider Selling: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Jun-17-24 07:00AM	Natera Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients (Business Wire)
Jun-10-24 02:25PM	Final Trades: Amazon, Natera and KKR (CNBC TV)
Jun-03-24 08:00AM	Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
02:42AM	Natera (NTRA) Raised Initial 2024 Guidance in Q1 (Insider Monkey)
Jun-01-24 03:24AM	Director Gail Marcus Sells 2,000 Shares of Natera Inc (NTRA) (GuruFocus.com)
May-31-24 03:13AM	Director Rowan Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
May-30-24 08:00AM	Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024 (Business Wire)
May-23-24 04:05PM	Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference (Business Wire)
07:30AM	Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting (Business Wire)
May-18-24 03:00AM	Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-11-24 01:02AM	Decoding Natera Inc (NTRA): A Strategic SWOT Insight (GuruFocus.com)
May-10-24 04:01PM	Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-Raise (Investor's Business Daily) +10.19%
01:58PM	Stocks to Watch Friday: TSMC, Novavax, Nvidia, Goldman Sachs (The Wall Street Journal)
12:24PM	Natera Inc (NTRA) Surpasses Analyst Revenue Forecasts in Q1 2024 (GuruFocus.com)
12:17PM	Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024 (Associated Press Finance)
12:04PM	Natera, Inc. (NASDAQ:NTRA) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:48AM	Natera Stock Charges Higher. Positive Cash Flow Arrived Early. (Barrons.com)
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:00AM	Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life (InvestorPlace)
May-09-24 06:30PM	Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 27 '25	Sale	161.87	1,442	233,417	108,032	Jan 29 09:45 PM
MICHAEL BURKES BROPHY	Officer	Jan 27 '25	Proposed Sale	167.61	1,442	241,694		Jan 27 04:24 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 24 '25	Sale	171.98	946	162,689	109,474	Jan 24 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 23 '25	Sale	171.09	495	84,690	110,420	Jan 24 09:45 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 22 '25	Sale	164.97	24,861	4,101,226	140,684	Jan 24 09:45 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 22 '25	Sale	164.97	21,228	3,501,905	147,230	Jan 24 09:45 PM
MICHAEL BURKES BROPHY	Officer	Jan 24 '25	Proposed Sale	171.82	946	162,542		Jan 24 04:18 PM
Sheena Jonathan	CO-FOUNDER	Jan 22 '25	Sale	165.00	971	160,214	261,745	Jan 22 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 22 '25	Sale	164.97	22,039	3,635,685	217,793	Jan 22 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 22 '25	Sale	164.97	78,553	12,958,585	267,629	Jan 22 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 22 '25	Sale	164.97	25,931	4,277,735	109,665	Jan 22 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 08 '25	Sale	175.30	6,223	1,090,901	199,804	Jan 10 09:35 PM
DANIEL RABINOWITZ	Officer	Jan 08 '25	Proposed Sale	170.40	6,223	1,060,399		Jan 08 04:23 PM
Sheena Jonathan	CO-FOUNDER	Jan 02 '25	Sale	159.55	3,000	478,645	44,782	Jan 03 09:55 PM
Sheena Jonathan	CO-FOUNDER	Jan 02 '25	Sale	159.44	2,700	430,480	254,372	Jan 03 09:55 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Dec 23 '24	Sale	159.60	669	106,773	114,142	Dec 26 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 23 '24	Sale	159.60	2,428	387,511	116,997	Dec 26 09:05 PM
Sheena Jonathan	CO-FOUNDER	Dec 18 '24	Sale	167.24	3,000	501,713	46,282	Dec 20 09:05 PM
Sheena Jonathan	CO-FOUNDER	Dec 18 '24	Sale	167.27	2,700	451,625	257,072	Dec 20 09:05 PM
Sheena Jonathan	Director	Dec 18 '24	Proposed Sale	150.00	17,100	2,565,000		Dec 18 11:33 AM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Dec 13 '24	Sale	165.74	160,000	26,518,750	2,389,180	Dec 13 09:35 PM
MATTHEW RABINOWITZ	Director	Dec 13 '24	Proposed Sale	166.45	160,000	26,632,000		Dec 13 04:25 PM
Chapman Rowan E	Director	Dec 10 '24	Sale	170.24	1,767	300,808	6,202	Dec 11 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 09 '24	Sale	166.59	4,858	809,312	114,912	Dec 11 09:05 PM
Chapman Rowan E	Officer	Dec 10 '24	Proposed Sale	170.24	1,767	300,808		Dec 10 03:08 PM
Moshkevich Solomon	Officer	Dec 09 '24	Proposed Sale	166.59	4,858	809,312		Dec 10 02:41 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Dec 05 '24	Option Exercise	5.40	68,496	369,556	2,549,180	Dec 09 04:05 PM
BOTHA ROELOF	Director	Dec 02 '24	Sale	169.12	87,473	14,793,563	1,224,787	Dec 04 05:13 PM
BV369 TRUST	Director	Dec 02 '24	Proposed Sale	169.12	87,473	14,793,565		Dec 02 04:58 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 25 '24	Sale	168.51	2,000	337,028	86,000	Nov 27 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 26 '24	Sale	164.17	2,000	328,348	84,000	Nov 27 09:05 PM
THE TINKERBELLE TRUST U/A DTD	Officer	Nov 26 '24	Proposed Sale	164.17	2,000	328,348		Nov 26 04:36 PM
THE TINKERBELLE TRUST U/A DTD	Officer	Nov 25 '24	Proposed Sale	168.51	2,000	337,028		Nov 25 06:37 PM
Marcus Gail Boxer	Director	Nov 19 '24	Sale	159.98	9,682	1,548,931	9,704	Nov 21 09:35 PM
Marcus Gail Boxer	Director	Nov 19 '24	Proposed Sale	159.98	9,682	1,548,931		Nov 19 05:19 PM
Baynes Roy D.	Director	Nov 15 '24	Option Exercise	23.48	37,230	874,177	53,037	Nov 15 09:50 PM
Baynes Roy D.	Director	Nov 15 '24	Sale	146.11	37,230	5,439,565	15,807	Nov 15 09:50 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 15 '24	Sale	146.41	4,728	692,209	185,034	Nov 15 09:50 PM
Sheena Jonathan	CO-FOUNDER	Nov 13 '24	Sale	153.54	20,000	3,070,769	259,772	Nov 15 09:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 13 '24	Sale	156.48	16,300	2,550,628	47,782	Nov 15 09:05 PM
Marcus Gail Boxer	Director	Nov 14 '24	Sale	158.53	2,212	350,672	19,386	Nov 15 09:05 PM
ROY D BAYNES	Director	Nov 15 '24	Proposed Sale	146.11	37,230	5,439,564		Nov 15 04:00 PM
STEVEN L CHAPMAN	Officer	Nov 15 '24	Proposed Sale	146.41	4,728	692,209		Nov 15 04:00 PM
Marcus Gail Boxer	Director	Nov 14 '24	Proposed Sale	158.53	2,212	350,672		Nov 14 05:37 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 11 '24	Option Exercise	5.40	130,000	701,389	2,470,684	Nov 13 09:50 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 12 '24	Option Exercise	5.40	10,000	53,953	2,480,684	Nov 13 09:50 PM
Sheena Jonathan	Director	Nov 13 '24	Proposed Sale	154.86	36,300	5,621,395		Nov 13 10:27 AM
Sheena Jonathan	CO-FOUNDER	Nov 08 '24	Sale	130.77	3,000	392,306	55,932	Nov 12 09:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 08 '24	Sale	130.80	2,700	353,165	279,772	Nov 12 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 31 '24	Sale	126.45	1,866	235,956	68,851	Nov 01 09:35 PM
MICHAEL BURKES BROPHY	Officer	Oct 31 '24	Proposed Sale	126.73	1,866	236,478		Oct 31 04:27 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 28 '24	Sale	118.21	1,057	124,948	206,027	Oct 30 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 28 '24	Sale	118.21	1,196	141,380	110,695	Oct 30 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 28 '24	Sale	118.21	929	109,818	113,136	Oct 30 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 28 '24	Sale	118.21	3,960	468,114	189,762	Oct 30 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 28 '24	Sale	118.21	1,238	146,345	71,471	Oct 30 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 29 '24	Sale	119.93	754	90,427	70,717	Oct 30 09:35 PM
MICHAEL BURKES BROPHY	Officer	Oct 29 '24	Proposed Sale	120.71	754	91,015		Oct 29 04:22 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 24 '24	Sale	119.19	914	108,940	73,400	Oct 25 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 25 '24	Sale	118.81	691	82,098	72,709	Oct 25 09:35 PM
MICHAEL BURKES BROPHY	Officer	Oct 24 '24	Proposed Sale	118.65	1,605	190,433		Oct 24 04:21 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 21 '24	Sale	120.76	294	35,503	112,147	Oct 23 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 22 '24	Sale	120.07	256	30,738	111,891	Oct 23 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 21 '24	Sale	120.76	342	41,299	114,264	Oct 23 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 22 '24	Sale	120.07	199	23,894	114,065	Oct 23 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 23 '24	Sale	119.09	496	59,068	74,314	Oct 23 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 21 '24	Sale	120.76	467	56,394	207,433	Oct 22 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 22 '24	Sale	120.07	349	41,904	207,084	Oct 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 21 '24	Sale	120.76	1,709	206,375	194,615	Oct 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 22 '24	Sale	120.07	893	107,223	193,722	Oct 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 21 '24	Sale	120.76	608	73,420	74,014	Oct 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 22 '24	Sale	120.07	454	54,512	73,560	Oct 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 15 '24	Sale	130.40	4,523	589,797	191,163	Oct 17 09:05 PM
STEVEN L CHAPMAN	Officer	Oct 15 '24	Proposed Sale	130.40	4,523	589,797		Oct 15 04:29 PM
Sheena Jonathan	CO-FOUNDER	Oct 01 '24	Sale	125.67	3,000	377,024	57,432	Oct 03 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 01 '24	Sale	125.60	2,700	339,113	282,041	Oct 03 09:05 PM
Sheena Jonathan	CO-FOUNDER	Sep 18 '24	Sale	127.61	19,300	2,462,787	58,932	Sep 20 09:35 PM
Sheena Jonathan	CO-FOUNDER	Sep 18 '24	Sale	127.57	2,700	344,450	284,741	Sep 20 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Sep 16 '24	Sale	128.48	5,024	645,474	195,686	Sep 18 09:35 PM
Sheena Jonathan	Director	Sep 18 '24	Proposed Sale	127.00	25,300	3,213,100		Sep 18 11:56 AM
Chapman Rowan E	Director	Sep 13 '24	Option Exercise	94.14	2,614	246,082	10,583	Sep 16 09:05 PM
Chapman Rowan E	Director	Sep 13 '24	Sale	127.68	2,614	333,756	7,969	Sep 16 09:05 PM
STEVEN L CHAPMAN	Officer	Sep 16 '24	Proposed Sale	128.48	5,024	645,473		Sep 16 04:28 PM
Chapman Rowan E	Director	Sep 13 '24	Proposed Sale	127.68	2,614	333,756		Sep 13 05:22 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Aug 15 '24	Sale	118.91	5,583	663,895	200,710	Aug 16 09:40 PM
Sheena Jonathan	CO-FOUNDER	Aug 15 '24	Sale	121.01	12,000	1,452,125	287,441	Aug 16 09:40 PM
STEVEN L CHAPMAN	Officer	Aug 15 '24	Proposed Sale	118.91	5,583	663,895		Aug 15 04:32 PM
Sheena Jonathan	CO-FOUNDER	Aug 12 '24	Sale	113.82	2,700	307,314	299,441	Aug 14 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Aug 13 '24	Sale	116.67	3,956	461,547	114,606	Aug 14 09:05 PM
Sheena Jonathan	Director	Aug 12 '24	Proposed Sale	117.68	22,800	2,683,200		Aug 12 10:40 AM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Aug 08 '24	Option Exercise	5.40	190,000	1,025,107	1,480,648	Aug 09 09:40 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 29 '24	Sale	102.77	1,057	108,623	206,400	Jul 31 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jul 29 '24	Sale	102.77	1,196	122,908	112,441	Jul 31 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jul 31 '24	Option Exercise	5.40	100	540	108,562	Jul 31 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jul 29 '24	Sale	102.77	929	95,469	108,462	Jul 31 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 29 '24	Sale	102.77	4,084	419,695	206,293	Jul 31 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 31 '24	Sale	99.65	1,866	185,947	71,955	Jul 31 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 29 '24	Sale	102.77	1,238	127,224	73,821	Jul 31 09:05 PM
MICHAEL BURKES BROPHY	Officer	Jul 31 '24	Proposed Sale	97.75	1,866	182,402		Jul 31 04:17 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 24 '24	Sale	105.53	918	96,877	76,500	Jul 26 09:40 PM

TVTX

Travere Therapeutics Inc

NTRA

Natera Inc

Upgrade your FINVIZ experience